Hemostemix AI Stock Analysis
Want to see TSE:HEM full AI Analyst Report?
Hemostemix (HEM) AI Stock Analysis
Hemostemix
(TSXV:HEM)
The overall score is at the absolute minimum of 37, driven by a complete absence of revenue, insolvent balance sheet, and accelerating cash burn. Technicals confirm a persistent downtrend with deeply bearish momentum, while negative earnings render traditional valuation metrics useless. The company faces extreme financial risk with no mitigating factors from earnings calls or corporate events.
Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 7.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 42.58K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.56
- Revenue Growth
- ―
- EPS Growth
- 16.04%
- Country
- Canada
- Employees
- 12
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Hemostemix Business Overview & Revenue Model
Company Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment...
Hemostemix Financial Statement Overview
Summary
Hemostemix exhibits severe financial distress with zero revenue, escalating net losses, negative stockholders' equity, and rapidly deteriorating cash flow. The company is insolvent and entirely dependent on external financing, reflecting the lowest possible financial health.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -33 | -46 | -100 | -223 | -495 | -1,101 |
| EBITDA | -4.30M | -4.26M | -1.98M | -1.95M | -4.39M | -6.45M |
| Net Income | -4.54M | -4.71M | -2.62M | -2.50M | -5.24M | -6.29M |
Balance Sheet | ||||||
| Total Assets | 257.07K | 846.90K | 991.86K | 313.76K | 465.35K | 563.05K |
| Cash, Cash Equivalents and Short-Term Investments | 196.46K | 741.72K | 705.70K | 155.42K | 135.75K | 219.44K |
| Total Debt | 3.56M | 3.60M | 4.94M | 4.32M | 4.13M | 1.48M |
| Total Liabilities | 6.02M | 5.82M | 8.20M | 7.68M | 7.23M | 5.85M |
| Stockholders Equity | -5.76M | -4.97M | -7.20M | -7.37M | -6.77M | -5.28M |
Cash Flow | ||||||
| Free Cash Flow | -5.27M | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Operating Cash Flow | -5.27M | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Investing Cash Flow | -304 | -145.88K | 0 | 0 | 0 | 171.12K |
| Financing Cash Flow | 4.73M | 4.66M | 2.45M | 1.44M | 6.02M | 3.27M |
Hemostemix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 27.27 is Positive, neither overbought nor oversold. The STOCH value of 41.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.
Hemostemix Peers Comparison
Overall Rating
TSE:BLAB52Neutral
TSE:PREV45Neutral
TSE:HEM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | CAD 11.36M | 0.76 | 101.66% | ― | ― | ― | |
| 45Neutral | CAD 15.95M | -20.83 | 10.15% | ― | ― | -36.36% | |
| 37Underperform | CAD 7.40M | -1.21 | 92.37% | ― | ― | 16.04% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:HEM | Hemostemix Inc | 0.04 | -0.05 | -58.82% | |
| TSE:IOT | Innovotech Inc | 0.09 | -0.13 | -58.72% | |
| TSE:BLAB | Britannia Life Sciences Inc | 0.07 | -0.02 | -26.32% | |
| TSE:PREV | PreveCeutical Medical | 0.03 | 0.00 | 0.00% |
Hemostemix Corporate Events
Hemostemix Wins Bahamas Approval for VesCell Trial and Advances Financing, Manufacturing
PositiveHemostemix has secured full approval from The Bahamas’ National Longevity and Regenerative Therapy Board, including ethics clearance, to run a commercial Phase 1 study of its VesCell therapy for angina, vascular dementia and pain, strengthening its p...
Hemostemix Advances $1 Million Private Placement to Fund Stem Cell Therapy Commercialization
PositiveHemostemix Inc. has moved to secure price protection as it prepares to close the third tranche of a previously announced non‑brokered private placement, aiming to raise $1 million through units comprising common shares and warrants listed on the TSX...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
